We propose to develop a novel drug conjugate from Hyaluronic acid (HA), a biomaterial ubiquitously present in our body, and Ethambutol and Isoniazid, two promising Mycobacterium (M) Tuberculosis (TB) drugs. However, in general, the TB drugs are not only associated with some toxicity but also the patients can develop resistance to the drug. The conjugates of HA and MTB drugs are expected to act synergistically to eliminate those shortcomings.
